This is a website for healthcare professionals.
Obtain Diagnostic Clarity with AVISE® CTD
Overlapping symptoms contribute to diagnostic uncertainty
Delays in diagnosis can lead to increased morbidity, higher mortality rates, and escalating healthcare costs. AVISE CTD addresses the challenge of overlapping symptoms by providing a comprehensive test to help you build the foundation for a diagnosis.
Just Two Tubes Provide Powerful Insights
With over 30 biomarkers carefully selected by rheumatologists for their diagnostic relevance, AVISE CTD helps improve diagnostic accuracy, reducing uncertainty and aiding in earlier diagnosis.
Here's how two tubes of blood can help you give your patients the answers they need:
1
CB-CAPs Biomarkers
EC4d • BC4d • TC4d *pending regulatory approval*
2
Proprietary Two-tier Algorithm
AVISE Lupus Index
3
Connective Tissue Disease Panel
RA • APS • MCTD • Sjögren's • Myositis • Systemic Sclerosis • Autoimmune Thyroid Disease • Lupus
Novel T Cell biomarkers provide enhanced diagnostic precision for patients with SLE
Pending regulatory approval
AVISE CTD includes a collection of SLE-specific biomarkers that provide unique insight when conventional biomarkers are negative.
These biomarkers are not orderable at this time. More details about their official launch date will be available soon.
Anti-RA33 autoantibodies deliver greater diagnostic clarity for seronegative RA patients
Pending regulatory approval
AVISE CTD's enhanced RA profile incorporates three new autoantibodies that can substantiate an RA diagnosis in the absence of anti-CCP and rheumatoid factor.
These biomarkers are not orderable at this time. More details about their official launch date will be available soon.
Learn more
Proprietary Lupus Algorithm
Using CB-CAPs and other SLE associated markers, AVISE Lupus employs an advanced algorithm and proprietary Index Value to help term isolated data points into actionable information. Developed using multivariate logistic regression, the index results is plotted on a spectrum associated with the likelihood of the presence of SLE.
Gain actionable insights
The AVISE CTD test report provides a comprehensive lineup of profiles, revealing the most salient information for your suspected autoimmune CTD patients.
Build confidence with reliable results
Exagen has extensive peer-reviewed literature supporting the clinical utility of its proprietary technology, demonstrating actionable results that support your diagnostic and treatment decisions.